Taro Pharma, a subsidiary of Sun Pharma, reported a net profit of $8.5 million for the July-September quarter, marking a significant improvement compared to a net loss of $2.8 million in the same period last year. However, the company’s bottomline was somewhat affected by one-time exceptional charges, and when excluding these charges, the net profit amounted to $14.3 million. In addition to the improved profitability, Taro Pharma also achieved an operating income of $4.7 million, contrasting with a loss of $6.8 million in the base period. Excluding the impact of the one-time exceptional item, the operating income reached $10.9 million. These positive earnings from Taro Pharma are expected to contribute to the consolidated growth of its parent company, Sun Pharma.
Where Industry Meet Trends
Menu
English